Tempest Therapeutics Inc Stock

$0.80

1.64% today

Nasdaq, Feb 28, 05:21 pm CET

ISIN

US87978U1088

Symbol

TPST

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Tempest Therapeutics Inc Stock price

$0.79

-114.56 99.31% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.04 4.40%

ISIN

US87978U1088

Symbol

TPST

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$34.51m
Enterprise Value	$30.13m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.83
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-35.62m
Free Cash Flow (TTM) Free Cash Flow	$-29.49m
Cash position	$22.12m
EPS (TTM) EPS	$-1.54
P/E forward	negative
Short interest	6.49%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Tempest Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Tempest Therapeutics Inc forecast:

5x Buy

100%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Tempest Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Tempest Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.43 0.43	80% 80% -
Gross Profit	-0.43 -0.43	80% 80% -
- Selling and Administrative Expenses	13 13	78% 78% -
- Research and Development Expense	22 22	14% 14% -
EBITDA	-35 -35	24% 24% -
- Depreciation and Amortization	0.43 0.43	80% 80% -
EBIT (Operating Income) EBIT	-36 -36	16% 16% -
Net Profit	-36 -36	14% 14% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tempest Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

18 days ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, ...

Neutral

GlobeNewsWire

●

21 days ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 45,000 shares of ...

Neutral

GlobeNewsWire

●

about 2 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ ant...

More Tempest Therapeutics Inc News

Company Profile

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Head office	United States
CEO	Stephen Brady
Employees	17
Founded	2011
Website	www.tempesttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now